Koji Haratani

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

Koji Haratani, Hidetoshi Hayashi, Yasutaka Chiba et al. · JAMA Oncology · 2017 · 978 citations

Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment

Koji Haratani, Hidetoshi Hayashi, Taro Tanaka et al. · Annals of Oncology · 2017 · 291 citations · Full text

Tumor Immune Microenvironment, Cancer Immunosurveillance, Medicine +11

Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in <i>EGFR</i> Mutation–Positive Non–Small Cell Lung Cancer

Kohsuke Isomoto, Koji Haratani, Hidetoshi Hayashi et al. · Clinical Cancer Research · 2020 · 233 citations

Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab

Junko Tanizaki, Koji Haratani, Hidetoshi Hayashi et al. · Journal of Thoracic Oncology · 2017 · 223 citations

Biomarker (Medicine), Prognostic Biomarkers, Oncology +9

LIS1 and NDEL1 coordinate the plus‐end‐directed transport of cytoplasmic dynein

Masami Yamada, Shiori Toba, Yuko Yoshida et al. · The EMBO Journal · 2008 · 190 citations · Full text